CD274 and neoplasm: The PMDDH significantly improves the pharmacokinetics and tumor‐targeting capabilities of Dox, while metformin enhances the drug's anti‐tumor activity by downregulating programmed cell death ligand 1 (PD‐L1) and activating the AMP‐activated protein kinase (AMPK) signaling pathway.